PROCEPT BioRobotics Corp. (PRCT), a surgical robotics company, has not only reported better-than-expected results for the third quarter but has also upgraded its 2024 revenue outlook for the third time, propelling its shares to an all-time high of $90.79 in today's trading.
The company manufactures and sells AquaBeam Robotic System and HYDROS Robotic System. The AquaBeam Robotic System is an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The HYDROS Robotic System is a next-generation, AI-powered platform for aquablation therapy, which received FDA clearance as recently as August of this year. Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet for the treatment of BPH.
For comments and feedback: editorial@rttnews.com